Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. II. The elevated plus-maze

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 2, 1997, Pages 295-303

  Rodgers, R J ^a   Cutler, M G ^b   Jackson, J E ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

Author keywords

animal models; antidepressants; anxiety; anxiolytics; buspirone; mice; ondansetron; plus maze; ti aneptine

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BUSPIRONE; ONDANSETRON; RECEPTOR SUBTYPE; SEROTONIN AGONIST; TIANEPTINE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUSPIRONE; MALE; MAZE LEARNING; MICE; ONDANSETRON; SEROTONIN AGONISTS; THIAZEPINES;

EID: 0031057420     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00242-0     Document Type: Article

References (77)

1. Andrews, N.; File, S. E. Handling history modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:109-112; 1993.
2. Ansseau, M. The paradox of neurochemical and clinical properties of serotonergic antidepressants. In: Langer, S. Z.; Brunello, N.; Racagni, G.; Mendlewicz, J., eds. Critical issues in the tretament of affective disorders. Basel: Karger; 1993:127-135.
3. Ballenger, J. C. Pharmacological treatment of panic disorder. In: DenBoer, J. A.; Sitsen J. M., eds. Handbook of depression and anxiety. New York: Marcel Dekker; 1994:275-289.
4. Barrett, J. E.; Vanover K. E. 5-Ht receptors as targets for the development of novel anxiolytic drugs: models, mechanisms and future directions. Psychopharmacology 112:1-12; 1992.
5. Bickerdike, M. J.; Marsden, C. A.; Dourish, C. T.; Fletcher, A. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. Eur. J. Pharmacol. 271:403-411; 1994.
6. Blanchard, R. J.; Shepherd, J. K.; Rodgers, R. J.; Magee, L.; Blanchard, D. C. Attenuation of antipredator defensive behavior in rats following chronic treatment with imipramine. Psychopharmacology 110:245-253; 1993.
7. Briley, M.; Chopin, P; Moret, C. The role of serotonin in anxiety: Behavioural approaches. In: Briley, M.; File, S. E., eds. New concepts in anxiety. London: MacMillan; 1991:56-73.
8. Briley, M.; Chopin, P.; Veigner, M. The plus-maze test of anxiety: Validation in different rat strains and effect of a wide range of antidepressants. Br. J. Pharmac. 87:217P; 1986.
9. Cadogan, A. K.; Wright, I. K.; Coombs, I.; Marsden, C. A.; Kendall, D. A.; Tulloch, I. Repeated paroxetine administration in the rat produces an anxiolytic profile in the elevated X-maze and a decreased (3H)-ketanserin binding. Neurosci. Lett. 42:S8; 1992.
10. Cole, J. C.; Burroughs, G. J.; Laverty, C. R.; Sheriff, N. C.; Sparham, E. A.; Rodgers, R. J. Anxiolytic-like effects of yohimbine in the murine elevated plus-maze: Strain independence and evidence against '2-adrenoceptor mediation. Psychopharmacology 118:425-436; 1995.
11. Cole, J. C.; Rodgers, R. J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4:573-580; 1993.
12. Cole, J. C.; Rodgers, R. J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: Comparison with haloperidol. Psychopharmacology 114:288-296; 1994.
13. Cole, J. C.; Rodgers, R. J. Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 52:473-478; 1995.
14. Commissaris, R. L.; Humrich, J.; Johns, J.; Geere, D. G.; Fontana, D. J. The effects of selective and non-selective monoamine oxidase (MAO) inhibitors on conflict behavior in the rat. Behav. Pharmacol. 6:195-202; 1995.
15. Costall, B.; Domeney, A. M.; Hughes, J.; Kelley, M. E.; Naylor, R. J.; Woodruff, G. N. Anxiolytic effects of CCK-B antagonists. Neuropeptides 19 (Suppl):65-73; 1991.
16. Costall, B.; Jones, B. J.; Kelly, M. E.; Naylor, R. J.; Tomkins, D. M. Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol. Biochem. Behav. 32:777-785; 1989.
17. 3 antagonists and benzodiazepines: Their comparative behavioural pharmacology. Chichester: Wiley; 1991:133-157.
18. Cruz, A. P. M.; Frei, F.; Graeff, F. G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:171-176; 1994.
19. Cutler, M. G.; Rodgers, R. J.; Jackson, J. E. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. I. Social Interaction. Pharmacol. Biochem. Behav., (in press.)
20. Cutler, M. G.; Rodgers, R. J.; Jackson, J. E. Behavioural effects in mice of subchronic buspirone, ondansetron and tianeptine. I. Social Interaction. Pharmacol. Biochem. Behav., in press.
21. DenBoer, J. A.; Westenberg, H. G. M.; De Leeuw, A. S.; van Vliet I. M. Biological dissection of anxiety disorders: The clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int. Clin. Psychopharmacol. 9 (Suppl 4):47-52; 1995.
22. Durcan, M. J.; Lister, R. G.; Eckhardt, M. J.; Linnoila, M. Behavioral interactions of fluoxetine, and other 5-hydroxytryptamine uptake inhibitors with ethanol in tests of anxiety, locomotion and exploration. Psychopharmacology 96:528-533; 1988.
23. File, S. E. Behavioural detection of anxiolytic action. In: Elliott, J. M.; Heal, D. J.; Marsden, C. A., eds. Experimental approaches to anxiety and depression. Chichester: Wiley; 1992:25-44.
24. File, S. E.; Johnston, A. L. Chronic treatment with imipramine does not reverse the effects of 3 anxiogenic compounds in a test of anxiety in the rat. Neuropsychobiology 17:187-192; 1987.
25. File, S. E.; Mabbutt, P. S. Effects of tianeptine in animal models of anxiety and on learning and memory. Drug Dev. Res. 23:47-56; 1991.
26. Fontana, D. J.; Carbary T. J.; Commissaris, R. L. Effects of acute and chronic anti-panic drug administration on conflict behavior in the rat. Psychopharmacology 98:157-162; 1989.
27. Gao, B.; Cutler, M. G. Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine and mianserin, on the social behaviour of mice. Neuropharmacology 33:813-824; 1994.
28. Gardner, C. Inhibition of ultrasonic distress vocalisations in rat pups by chlordiazepoxide and diazepam. Drug Dev. Res. 5:185-193; 1985.
29. 3 receptor antagonists: A critical update on therapeutic potential. TIPS:14; 265-270; 1994.
30. Griebel, G. 5-hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmac. Ther. 65:319-395; 1995.
31. Griebel, G.; Blanchard, D. C.; Agnes, R. S.; Blanchard, R. J. Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57-66; 1995.
32. Griebel, G.; Moreau, J-L.; Jenck, F.; Misslin, R.; Martin, J. R. Acute and chronic treatment with 5-HT reuptake inhibitors differentially modulate emotional responses in anxiety models in rodents. Psychopharmacology 113:463-470; 1994.
33. Guelfi, J. D.; Pichot, P.; Dreyfus, J. F. Efficacy of tianeptine in anxious-depressed patients: Results of a controlled multicenter trial versus amitriptyline. Neuropsychobiology 22:41-48; 1989.
34. Handley, S. L. 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmac. Ther. 66:103-148; 1995.
35. Handley, S.; McBlane, J. W. Opposite efffects of fluoxetine in two animal models of anxiety. Br. J. Pharmacol. 107:446P; 1992.
36. Hijzen, T. H.; Houtzager, S. W. J.; Joordens, R. J. E.; Olivier, B.; Slangen, J. L. Predictive validity of the potentiated startle response as a behavioural model for anxiolytic drugs. Psychopharmacology 118:150-154; 1995.
37. Hoehn-Saric, R.; McLeod, D. R. Depression and anxiety: is there a common etiology? In: DenBoer, J. A.; Sitsen, J. M., eds. Handbook of depresson and anxiety. New York: Marcel Dekker; 1994:119-158.
38. Howard, J. L.; Pollard, G. T. Effects of buspirone in the Geller-Seifter conflict test with incremental shock. Drug Dev. Res. 19:37-49; 1990.
39. Invernizzi, G.; Aguglia, E.; Bertolino, A.; Casacchia, M.; Ciani, N.; Marchesi, G. F.; Nardini, M.; Rapisarda, V. The efficacy and safety of tianeptine in the treatment of depressive disorder: Results of a controlled double-blind multicentre study vs amitriptyline. Neuropsychobiology 30:85-93; 1994.
40. Johnson, N. J. T.; Rodgers, R. J. Ethological analysis of cholecystokinin (CCKA & CCKB) receptor ligands in the elevated plusmaze test of anxiety in mice. Psychopharmacology 124:355-364; 1996.
41. Johnston, A. L.; File, S. E. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiat. Res. 25:81-90; 1988.
42. Kahn, R. J.; McNair, D. M.; Lipman, R. S.; Covi, L.; Rickels, K.; Downing, R.; Fisher, S.; Frankenthaler, L. M. Imipramine and chlordiazepoxide in depressive and anxiety disorders: II: Efficacy in anxious outpatients. Arch. Gen. Psychiat. 43:79-85; 1986.
43. Kasper, S. Neurobiology and new psychopharmacological strategies for treatment of anxiety disorders. In: Darcourt, G.; Mendlewicz, J.; Racagni, G.; Brunello, N., eds. Current therapeutical approaches to panic and other anxiety disorders. Basel: Karger; 1994:15-35.
44. Kendler, K. S.; Neale, M. C.; Kessler, R. C.; Heath, A. C.; Eaves, L. J. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch. Gen. Psychiat. 49:716-722; 1992.
45. Kilts, C. D.; Commissaris, R. L.; Rech, R. H. Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology 74:290-296; 1981.
46. 3 antagonist, in the treatment of psychiatric disorders: June 9 1991; Florence; 17-19.
47. Lecrubier, V.; Puech, A. J.; Azcona A.; Bailey, P. E.; Lataste, X. A randomized double-blind placebo-controlled study of tropisetronin the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 112:129-133; 1993.
48. Lister, R. G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185; 1987.
49. Loo, H.; Deniker, P. Position of tianeptine among antidepressive chemotherapies. Clin. Psychopharmacol. 11:Suppl 2; S97-S102; 1988.
50. Martin, J. R.; Moreau, J.-L.; Jenck, F.; Cumin, R. Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm. Pharmacol. Biochem. Behav. 46:905-910; 1993.
51. Mennini, T.; Mocaer, E.; Garattini, S. Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn-Schmeideberg's Arch. Pharmacol. 336:478-482; 1987.
52. 3 antagonist, ondansetron, in panic disorder. Presented at the ACNP conference; Dec 12-16 1994; Puerto Rico.
53. Moser, P. An evaluation of of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology 99:48-53; 1989.
54. Noyes, R. The comorbidity and mortality of panic disorder. Psychiat. Med. 8:41-66; 1990.
55. Nutt, D. J.; Glue, P. Clinical pharmacology of anxiolytics and antidepressants: A psychopharmacological perspective. Pharmac. Ther. 44:309-334; 1989.
56. Nutt, D. J.; Lawson, C. Panic attacks: A neurochemical overview of models and mechanisms. Br. J. Psychiat. 160:165-178; 1992.
57. Pappas, B. A.; Vogel, R. A.; Frye, G. D.; Breese, G. R.; Mueller, R. A. Stimulant drugs enhance effects of punishment in normal and chlordiazepoxide-treated rats. Soc. Neurosci. Abstr. 4, 1978.
58. Pecknold, J. C. Serotonin abnormalities in panic disorder. In: Ballenger, J. C., ed. Neurobiology of panic disorder. New York: Wiley-Liss; 1990:121-142.
59. Pellow, S.; Chopin, P.; File, S. E.; Briley, M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14:149-167; 1985.
60. Pellow, S.; File S. E. Can anti-panic drugs antagonize the anxiety produced in the rat by drugs acting at the GABA-benzodiazepine receptor complex? Neuropsychobiology 17:60-65; 1987.
61. Rickels, K.; Downing R.; Schweizer, E.; Hassman, H. Antidepressants for the treatment of generalized anxiety disorder. Arch. Gen. Psychiat. 50:884-895; 1993.
62. Rickels, K.; Schweizer, E. Current pharmacotherapy of anxiety and panic. In: Meltzer, H. ed Psychopharmacology: The third generation of progress. New York: Raven Press; 1987:1193-1203.
63. Rocha, B.; Rigo, M.; Di Scala G.; Sandner, G.; Hoyer, D. Chronic mianserin or eltoprazine treatment in rats: Effects on the elevated plus-maze test and on limbic 5-HT2C receptor levels. Eur. J. Pharmacol. 262:125-131; 1994.
64. Rodgers, R. J.; Cole, J. C. The elevated plus-maze: Pharmacology, methodology and ethology. In: Cooper, S. J.; Hendrie, C. A., eds. Ethology and psychopharmacology. Chichester: John Wiley and Sons; 1994:9-44.
65. Rodgers, R. J.; Cole, J. C.; Aboualfa, K.; Stephenson, L. H. Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol. Biochem. Behav. 52:805-813.
66. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety on mice. Psychopharmacology 117:306-312; 1995.
67. Rodgers, R. J.; Cutler, M. G.; Jackson, J. E. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol. Biochem. Behav., (in press.)
68. Rodgers, R. J.; Johnson, N. J. T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:297-303; 1995.
69. Sheehan, D. V. The tricyclic antidepressants in the treatment of panic and anxiety disorders. Psychosomatics 27:10-16; 1986.
70. Taylor, D. P.; Moon, S. L. Buspirone and related compounds as alternative anxiolytics. Neuropeptides 19 (Suppl 1); 15-19; 1991.
71. 3 antagonists and benzodiazepines: Their comparative behavioural pharmacology. Chichester: Wiley; 1991:107-131.
72. Treit, D.; Menard, J.; Royan, C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. behav. 44:463-469; 1993.
73. Tyrer, P.; Tyrer, J. Antidepressive drugs for the treatment of anxiety disorders - and vice versa. In: DenBoer, J. A.; Sitsen, J. M. A., eds. Handbook of depression and anxiety. New York: Marcel Dekker; 1994:497-514.
74. De Vry, J.; Benz, U.; Schreiber, R.; Traber, J. Shock-induced ultrasonic vocalization in young adult rats: A model for testing putative anti-anxiety drugs. Eur. J. Pharmacol. 249:331-339; 1993.
75. Westenberg, H. G. M.; DenBoer, J.A. The neuropharmacology of anxiety: A review of the role of serotonin. In: DenBoer, J. A.; Sitsen, J. M. A., eds. Handbook of depression and anxiety. New York: Marcel Dekker; 1994:405-446.
76. Wilde, M. I.; Benfield, P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49:411-439; 1995.
77. Wilde, M. I.; Benfield, P. Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 49:411-439; 1995.